B. Riley Has Optimistic Outlook of DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – B. Riley lifted their FY2025 earnings per share estimates for shares of Denali Therapeutics in a report issued on Thursday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($3.02) for the year, up from their previous forecast of ($3.08). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2026 earnings at ($3.24) EPS, FY2027 earnings at ($2.48) EPS, FY2028 earnings at $1.98 EPS and FY2029 earnings at ($0.80) EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) EPS.

DNLI has been the topic of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. TD Cowen upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Morgan Stanley cut their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $32.64.

Denali Therapeutics Stock Up 1.7%

Shares of Denali Therapeutics stock opened at $17.44 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The firm’s 50-day moving average is $15.26 and its two-hundred day moving average is $14.72. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $28.62. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -5.99 and a beta of 1.39.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DNLI. Headlands Technologies LLC acquired a new position in Denali Therapeutics in the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the third quarter worth about $29,000. State of Wyoming purchased a new stake in shares of Denali Therapeutics during the second quarter worth about $29,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Denali Therapeutics in the 1st quarter valued at about $41,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.